ESR1 and essential thrombocythemia: This review emphasizes the structural features of ERs, particularly how the structure-function relationship of the ERα−LBD governs receptor activity, the role of activating ESR1 mutations in driving constitutive signaling, and the development of next-generation therapeutics—especially those targeting ERα mutants and GPER—to simultaneously antagonize both receptor classes implicated in ET resistance.